Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Binds IL-5 with high affinity and prevents IL-5 from interacting with its receptor on eosinophils, reducing eosinophil maturation, survival and inflammatory activity. Its extended duration supports dosing every six months.
Indications / reported uses
Add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adults and paediatric patients aged 12 years and older under the US FDA indication; not for acute bronchospasm or status asthmaticus
Add-on therapy with intranasal corticosteroids for severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults under the EMA/Australian product indications where systemic corticosteroids and/or surgery have not provided adequate control
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Depemokimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Depemokimab Permitted Daily Exposure (PDE) report (the Depemokimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Depemokimab Occupational Exposure Limit (OEL) report (the Depemokimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.